Process map** in healthcare: a systematic review

G Antonacci, L Lennox, J Barlow, L Evans… - BMC health services …, 2021 - Springer
Introduction Process map** (PM) supports better understanding of complex systems and
adaptation of improvement interventions to their local context. However, there is little …

Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change

BR Luce, JM Kramer, SN Goodman… - Annals of internal …, 2009 - acpjournals.org
This companion article to Sox and Greenfield's report describes better research methods for
CER. It addresses the fundamental limitations of traditional randomized, controlled trials for …

[PDF][PDF] Ethical and scientific implications of the globalization of clinical research

SW Glickman, JG McHutchison, ED Peterson… - N Engl J …, 2009 - researchgate.net
Ethical and Scientific Implications of the Globalization of Clinical Research Page 1 sounding
board The new england journal of medicine n engl j med 360;8 nejm.org february 19, 2009 …

Oligometastases: emerging evidence

W Liu, H Bahig, DA Palma - Journal of Clinical Oncology, 2022 - ascopubs.org
The hypothesis that ablative therapies (such as surgery or radiation) can be used to cure
patients with a limited number of metastases was influential in changing practice. Early …

Perspectives on the development of imatinib and the future of cancer research

BJ Druker - Nature medicine, 2009 - nature.com
I am incredibly fortunate. To receive an award from the Lasker Foundation, with its
preeminent jury, is indeed an honor. But the greatest reward is seeing patients every week …

A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) …

SK Cheng, MS Dietrich, DM Dilts - Clinical Cancer Research, 2010 - aacrjournals.org
Purpose: Postactivation barriers to oncology clinical trial accruals are well documented;
however, potential barriers prior to trial opening are not. We investigate one such barrier …

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials

AT Schroen, GR Petroni, H Wang, R Gray… - Clinical …, 2010 - journals.sagepub.com
Background A major challenge for randomized phase III oncology trials is the frequent low
rates of patient enrollment, resulting in high rates of premature closure due to insufficient …

Equipoise lost: ethics, costs, and the regulation of cancer clinical research

DJ Stewart, SN Whitney, R Kurzrock - Journal of clinical oncology, 2010 - ascopubs.org
Cancer is the leading cause of death in Americans younger than 85 years of age and kills
one American every 56 seconds. Advances in understanding of cancer biology have given …

A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group

AP Abernethy, NM Aziz, E Basch, J Bull… - Journal of palliative …, 2010 - liebertpub.com
Background: Palliative medicine has made rapid progress in establishing its scientific and
clinical legitimacy, yet the evidence base to support clinical practice remains deficient in …

Analysis of start-up, retention, and adherence in ALS clinical trials

N Atassi, P Yerramilli-Rao, J Szymonifka, H Yu… - Neurology, 2013 - neurology.org
Objective: To investigate predictors of trial start-up times, high attrition, and poor protocol
adherence in amyotrophic lateral sclerosis (ALS) trials. Methods: Retrospective analysis of …